Jinghui Dong
Chinese PLA General Hospital
16 Papers
10 Citations
Jinghui Dong is an academic researcher from Chinese PLA General Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2.
Yu-Huan Xu,Jinghui Dong,Weimin An,Xiao-Yan Lv,Xiao-Ping Yin,Jianzeng Zhang,Li Dong,Xi Ma,Hong-Jie Zhang,Bu-Lang Gao +9 more
TL;DR: CT imaging presentations of NCP are mostly patchy ground glass opacities in the peripheral areas under the pleura with partial consolidation which will be absorbed with formation of fibrotic stripes if improved.
552
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
Sattva S. Neelapu,Michael Dickinson,Javier Munoz,M. Ulrickson,Catherine Thieblemont,Olalekan O. Oluwole,Alex F. Herrera,Chaitra S. Ujjani,Yi Lin,Peter A. Riedell,Natasha Kekre,Sven de Vos,C. Lui,Francesca Milletti,Jinghui Dong,Hairong Xu,Julio C. Chavez +16 more
TL;DR: In this paper , axicabtagene ciloleucel (axi-cel) was used as part of first-line therapy for high-risk large B-cell lymphoma (LBCL) patients.
5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1).
Sattva S. Neelapu,Caron A. Jacobson,Armin Ghobadi,David B. Miklos,Lazaros J. Lekakis,Olalekan O. Oluwole,Yi-Chung Lin,Ira Braunschweig,Brian T. Hill,John M. Timmerman,Abhinav Deol,Patrick M. Reagan,Patrick J. Stiff,Ian W. Flinn,Umar Farooq,Andre Goy,Peter A. McSweeney,Javier Munoz,Tanya Siddiqi,Julio C. Chavez,Alex F. Herrera,Nancy L. Bartlett,Adrian A Bot,Rhine R. Shen,Jinghui Dong,Kanwarjit J. Singh,Harry Miao,Jenny J. Kim,Yan Zheng,Frederick L. Locke +29 more
TL;DR: In this paper , axicabtagene ciloleucel (axi-cel) autologous anti-CD19 CAR T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL).
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
Bijal D. Shah,Armin Ghobadi,Olalekan O. Oluwole,Aaron C Logan,Nicolas Boissel,Ryan D. Cassaday,Thibaut Leguay,Michael R. Bishop,Max S. Topp,Dimitrios Tzachanis,Kristen M. O'Dwyer,Martha Arellano,Yi-Chung Lin,Maria R. Baer,Gary J. Schiller,Jae H. Park,Marion Subklewe,Mehrdad Abedi,Monique C. Minnema,William G. Wierda,Daniel J. DeAngelo,Patrick J. Stiff,Deepa Jeyakumar,Jinghui Dong,Sabina Adhikary,Lang Zhou,Petra C Schuberth,I. Faghmous,Behzad Kharabi Masouleh,Roch Houot +29 more
TL;DR: In this paper , the authors report updated ZUMA-3 outcomes with longer follow-up and an extended data set along with contextualization of outcomes to historical standard of care.
Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL)
Caron A. Jacobson,Frederick L. Locke,Armin Ghobadi,David B. Miklos,Lazaros J. Lekakis,Olalekan O. Oluwole,Yi Lin,Brian T. Hill,John M. Timmerman,Abhinav Deol,Patrick M. Reagan,Patrick J. Stiff,Ian W. Flinn,Umar Farooq,Andre Goy,Javier Munoz,Tanya Siddiqi,Rhine R. Shen,Adrian Bot,Jinghui Dong,Kanwarjit J. Singh,Clare Spooner,Roshan Karalliyadda,Jenny J. Kim,Yan Zheng,Sattva S. Neelapu +25 more
11